{"transactions":[{"id":2764527,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-04-01T19:58:39.000Z","date":"2021-04-01","kind":"disposition_to_issuer","acquired":false,"shares":73789,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All options were vested and exercisable as of immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":17.75,"expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":73789},"source":{"system":"sec-edgar","filing":"0000899243-21-014466","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924321014466/doc4.xml","form_type":"4"}},{"id":2764526,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-04-01T19:58:39.000Z","date":"2021-04-01","kind":"disposition_to_issuer","acquired":false,"shares":28227,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All options were vested and exercisable as of immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":28227},"source":{"system":"sec-edgar","filing":"0000899243-21-014466","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924321014466/doc4.xml","form_type":"4"}},{"id":2764525,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-04-01T19:58:39.000Z","date":"2021-04-01","kind":"other","acquired":false,"shares":87764,"price":60,"value":5265840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the \"Company\"), Merck Sharp & Dohme Corp. (\"Merck\") and Panama Merger Sub, Inc. (\"Merger Sub\"), Merger Sub commenced a tender offer (the \"Offer\") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the \"Offer Price\"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the \"Merger\") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014466","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924321014466/doc4.xml","form_type":"4"}},{"id":2802480,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-08T19:10:14.000Z","date":"2021-03-05","kind":"purchase","acquired":true,"shares":1000,"price":70,"value":70000.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001209191-21-018758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000120919121018758/doc4.xml","form_type":"4"}},{"id":2869494,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-10T16:41:32.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":73789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on February 8, 2021. 1/4 of the shares underlying the award shall vest on February 8, 2022, with the remainder of the shares vesting in equal monthly installments following February 8, 2022 through February 8, 2025, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":73789,"derivative":{"exercise_price":17.75,"expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":73789},"source":{"system":"sec-edgar","filing":"0000899243-21-005681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924321005681/doc4.xml","form_type":"4"}},{"id":3078839,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Series B Preferred Stock","published_at":"2020-07-21T19:39:10.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":35922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7044},"source":{"system":"sec-edgar","filing":"0000899243-20-019873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019873/doc4.xml","form_type":"4"}},{"id":3078838,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-21T19:39:10.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":10486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option award was granted on June 25, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":10486,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":10486},"source":{"system":"sec-edgar","filing":"0000899243-20-019873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019873/doc4.xml","form_type":"4"}},{"id":3078837,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-21T19:39:10.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":13935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":13935,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":13935},"source":{"system":"sec-edgar","filing":"0000899243-20-019873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019873/doc4.xml","form_type":"4"}},{"id":3078836,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-21T19:39:10.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":3806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on August 1, 2020, with the remainder of the shares vesting in equal monthly installments following August 1, 2020 through August 1, 2023, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":3806,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":3806},"source":{"system":"sec-edgar","filing":"0000899243-20-019873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019873/doc4.xml","form_type":"4"}},{"id":3078835,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-21T19:39:10.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":1450,"price":18,"value":26100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share."}],"balance_after":87764,"source":{"system":"sec-edgar","filing":"0000899243-20-019873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019873/doc4.xml","form_type":"4"}},{"id":3078834,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-21T19:39:10.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":7044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":86314,"source":{"system":"sec-edgar","filing":"0000899243-20-019873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807901/000089924320019873/doc4.xml","form_type":"4"}},{"id":3103870,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-06-19T18:25:29.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on June 18, 2021, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":12000,"derivative":{"exercise_price":22.96,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-038053","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000120919120038053/doc4.xml","form_type":"4"}},{"id":3448667,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2019-08-02T16:17:17.000Z","date":"2019-08-01","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on June 26, 2020, and then 9.375% of the remaining shares shall vest quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":24000,"derivative":{"exercise_price":22.8,"expiration_date":"2029-08-01","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001179110-19-009026","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000117911019009026/edgar.xml","form_type":"4"}},{"id":3474281,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-07-01T19:23:05.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":830489,"ownership":{"direct":false,"nature":"By S.R. One, Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein.  Vikas Goyal holds the title of Principal at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc.  Mr. Goyal disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":830489},"source":{"system":"sec-edgar","filing":"0001179110-19-008261","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000117911019008261/edgar.xml","form_type":"4"}},{"id":3474280,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-07-01T19:23:05.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":1469950,"ownership":{"direct":false,"nature":"By S.R. One, Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein.  Vikas Goyal holds the title of Principal at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc.  Mr. Goyal disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1469950},"source":{"system":"sec-edgar","filing":"0001179110-19-008261","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000117911019008261/edgar.xml","form_type":"4"}},{"id":3474279,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T19:23:05.000Z","date":"2019-07-01","kind":"purchase","acquired":true,"shares":333333,"price":15,"value":4999995.0,"ownership":{"direct":false,"nature":"By S.R. One, Limited"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein.  Vikas Goyal holds the title of Principal at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc.  Mr. Goyal disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":2633772,"source":{"system":"sec-edgar","filing":"0001179110-19-008261","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000117911019008261/edgar.xml","form_type":"4"}},{"id":3474278,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T19:23:05.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":830489,"ownership":{"direct":false,"nature":"By S.R. One, Limited"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein.  Vikas Goyal holds the title of Principal at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc.  Mr. Goyal disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":2300439,"source":{"system":"sec-edgar","filing":"0001179110-19-008261","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000117911019008261/edgar.xml","form_type":"4"}},{"id":3474277,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T19:23:05.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":1469950,"ownership":{"direct":false,"nature":"By S.R. One, Limited"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into one share of the issuer's Common Stock on July 1, 2019 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein.  Vikas Goyal holds the title of Principal at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc.  Mr. Goyal disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":1469950,"source":{"system":"sec-edgar","filing":"0001179110-19-008261","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000117911019008261/edgar.xml","form_type":"4"}},{"id":4170261,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C preferred stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"exercise","acquired":false,"shares":3683045,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":606024},"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}},{"id":4170260,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B preferred stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"exercise","acquired":false,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":328992},"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}},{"id":4170259,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A preferred stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"exercise","acquired":false,"shares":982906,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":246272},"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}},{"id":4170258,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Junior preferred stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"exercise","acquired":false,"shares":1483784,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":244147},"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}},{"id":4170257,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"purchase","acquired":true,"shares":428571,"price":14,"value":5999994.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of the Issuer's common stock that were purchased in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":1854006,"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}},{"id":4170256,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"exercise","acquired":true,"shares":606024,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":1425435,"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}},{"id":4170255,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"exercise","acquired":true,"shares":328992,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":819411,"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}},{"id":4170254,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"exercise","acquired":true,"shares":246272,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":490419,"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}},{"id":4170253,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":140696,"kind":"person","name":"Goyal Vikas","position":1,"cik":"0001721017","reported_name":"Goyal Vikas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-07T21:06:22.000Z","date":"2017-11-06","kind":"exercise","acquired":true,"shares":244147,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017).  The preferred stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Vikas Goyal is a Principal at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. Goyal disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":244147,"source":{"system":"sec-edgar","filing":"0000899243-17-025508","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924317025508/doc4.xml","form_type":"4"}}]}